{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:59:03Z","timestamp":1792159143657,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172949"],"award-info":[{"award-number":["82172949"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372650"],"award-info":[{"award-number":["82372650"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972569"],"award-info":[{"award-number":["81972569"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Nasopharyngeal carcinoma (NPC)-mediated immunosuppression within the tumor microenvironment (TME) frequently culminates in the failure of otherwise promising immunotherapies. In this study, we identify tumor-intrinsic FLI1 as a critical mediator in impairing T cell anti-tumor immunity. A mechanistic inquiry reveals that FLI1 orchestrates the expression of CBP and STAT1, facilitating chromatin accessibility and transcriptional activation of IDO1 in response to T cell-released IFN-\u03b3. This regulatory cascade ultimately leads to augmented IDO1 expression, resulting in heightened synthesis of kynurenine (Kyn) in tumor cells. This, in turn, fosters CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell exhaustion and regulatory T cell (Treg) differentiation. Intriguingly, we find that pharmacological inhibition of FLI1 effectively obstructs the CBP\/STAT1-IDO1-Kyn axis, thereby invigorating both spontaneous and checkpoint therapy-induced immune responses, culminating in enhanced tumor eradication. In conclusion, our findings delineate FLI1-mediated Kyn metabolism as an immune evasion mechanism in NPC, furnishing valuable insights into potential therapeutic interventions.\n                  <\/jats:p>","DOI":"10.1038\/s41467-024-48397-9","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T06:23:29Z","timestamp":1717050209000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["FLI1 promotes IFN-\u03b3-induced kynurenine production to impair anti-tumor immunity"],"prefix":"10.1038","volume":"15","author":[{"given":"Enni","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wancui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagui","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingbo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3538-8231","authenticated-orcid":false,"given":"Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4800-6025","authenticated-orcid":false,"given":"Fangyun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuguo","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,30]]},"reference":[{"key":"48397_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","volume":"394","author":"YP Chen","year":"2019","unstructured":"Chen, Y. P. et al. Nasopharyngeal carcinoma. Lancet 394, 64\u201380 (2019).","journal-title":"Lancet"},{"key":"48397_CR2","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1038\/s41422-020-0374-x","volume":"30","author":"YP Chen","year":"2020","unstructured":"Chen, Y. P. et al. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 30, 1024\u20131042 (2020).","journal-title":"Cell Res."},{"key":"48397_CR3","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","volume":"19","author":"W Fang","year":"2018","unstructured":"Fang, W. et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 19, 1338\u20131350 (2018).","journal-title":"Lancet Oncol."},{"key":"48397_CR4","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","volume":"35","author":"C Hsu","year":"2017","unstructured":"Hsu, C. et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J. Clin. Oncol. 35, 4050\u20134056 (2017).","journal-title":"J. Clin. Oncol."},{"key":"48397_CR5","doi-asserted-by":"publisher","first-page":"105127","DOI":"10.1016\/j.oraloncology.2020.105127","volume":"113","author":"D Johnson","year":"2021","unstructured":"Johnson, D. & Ma, B. B. Y. Targeting the PD-1\/ PD-L1 interaction in nasopharyngeal carcinoma. Oral Oncol. 113, 105127 (2021).","journal-title":"Oral Oncol."},{"key":"48397_CR6","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","volume":"124","author":"H Raskov","year":"2021","unstructured":"Raskov, H. et al. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br. J. Cancer 124, 359\u2013367 (2021).","journal-title":"Br. J. Cancer"},{"key":"48397_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15207","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-\u03b3-induced immunologic dormancy of tumor-repopulating cells. Nat. Commun. 8, 15207 (2017).","journal-title":"Nat. Commun."},{"key":"48397_CR8","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.semcancer.2022.10.001","volume":"86","author":"R Kant","year":"2022","unstructured":"Kant, R. et al. Deregulated transcription factors in cancer cell metabolisms and reprogramming. Semin. Cancer Biol. 86, 1158\u20131174 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"48397_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-020-00235-2","volume":"5","author":"Y Dong","year":"2020","unstructured":"Dong, Y. et al. Regulation of cancer cell metabolism: oncogenic MYC in the driver\u2019s seat. Signal Transduct. Target Ther. 5, 124 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"48397_CR10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/jmcb\/mjy070","volume":"11","author":"J Liu","year":"2019","unstructured":"Liu, J. et al. Tumor suppressor p53 and metabolism. J. Mol. Cell Biol. 11, 284\u2013292 (2019).","journal-title":"J. Mol. Cell Biol."},{"key":"48397_CR11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/nrc906","volume":"2","author":"JE Darnell Jr","year":"2002","unstructured":"Darnell, J. E. Jr Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2, 740\u2013749 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"48397_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41568-019-0196-7","volume":"19","author":"JH Bushweller","year":"2019","unstructured":"Bushweller, J. H. Targeting transcription factors in cancer - from undruggable to reality. Nat. Rev. Cancer 19, 611\u2013624 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"48397_CR13","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat. Med. 27, 802\u2013805 (2021).","journal-title":"Nat. Med."},{"key":"48397_CR14","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman, D. A. et al. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J. Clin. Oncol. 39, 1584\u20131594 (2021).","journal-title":"J. Clin. Oncol."},{"key":"48397_CR15","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-19-1668","volume":"81","author":"L Huang","year":"2021","unstructured":"Huang, L. et al. Targeting Pan-ETS Factors Inhibits Melanoma Progression. Cancer Res. 81, 2071\u20132085 (2021).","journal-title":"Cancer Res."},{"key":"48397_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41590-020-00850-9","volume":"22","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor. Nat. Immunol. 22, 358\u2013369 (2021).","journal-title":"Nat. Immunol."},{"key":"48397_CR17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","volume":"38","author":"J Si","year":"2020","unstructured":"Si, J. et al. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. Cancer Cell 38, 551\u2013566.e11 (2020).","journal-title":"Cancer Cell"},{"key":"48397_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41573-019-0016-5","volume":"18","author":"M Platten","year":"2019","unstructured":"Platten, M. et al. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat. Rev. Drug Discov. 18, 379\u2013401 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"48397_CR19","doi-asserted-by":"publisher","first-page":"102461","DOI":"10.1016\/j.ctrv.2022.102461","volume":"110","author":"Y Fujiwara","year":"2022","unstructured":"Fujiwara, Y. et al. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treat Rev. 110, 102461 (2022).","journal-title":"Cancer Treat Rev."},{"key":"48397_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41218-5","volume":"14","author":"Z Ma","year":"2023","unstructured":"Ma, Z. et al. AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer. Nat. Commun. 14, 5415 (2023).","journal-title":"Nat. Commun."},{"key":"48397_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.tips.2017.11.007","volume":"39","author":"JE Cheong","year":"2018","unstructured":"Cheong, J. E. & Sun, L. Targeting the IDO1\/TDO2-KYN-AhR Pathway for Cancer Immunotherapy - Challenges and Opportunities. Trends Pharmacol. Sci. 39, 307\u2013325 (2018).","journal-title":"Trends Pharmacol. Sci."},{"key":"48397_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17750-z","volume":"11","author":"LF Campesato","year":"2020","unstructured":"Campesato, L. F. et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nat. Commun. 11, 4011 (2020).","journal-title":"Nat. Commun."},{"key":"48397_CR23","doi-asserted-by":"publisher","first-page":"880","DOI":"10.3389\/fimmu.2017.00880","volume":"8","author":"EF de Ara\u00fajo","year":"2017","unstructured":"de Ara\u00fajo, E. F. et al. The IDO-AhR Axis Controls Th17\/Treg Immunity in a Pulmonary Model of Fungal Infection. Front. Immunol. 8, 880 (2017).","journal-title":"Front. Immunol."},{"key":"48397_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33285-x","volume":"13","author":"D Shi","year":"2022","unstructured":"Shi, D. et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat. Commun. 13, 5644 (2022).","journal-title":"Nat. Commun."},{"key":"48397_CR25","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2021.02.019","volume":"184","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. In vivo CD8(+) T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell 184, 1262\u20131280.e22 (2021).","journal-title":"Cell"},{"key":"48397_CR26","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012291","volume":"12","author":"W Tao","year":"2020","unstructured":"Tao, W. et al. SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells. EMBO Mol. Med. 12, e12291 (2020).","journal-title":"EMBO Mol. Med."},{"key":"48397_CR27","doi-asserted-by":"crossref","unstructured":"Zhou, Y. et al. Activation of NF-\u03baB and p300\/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc. Natl Acad. Sci. USA 118, e2025840118 (2021).","DOI":"10.1073\/pnas.2025840118"},{"key":"48397_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","volume":"14","author":"K Tang","year":"2021","unstructured":"Tang, K. et al. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J. Hematol. Oncol. 14, 68 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"48397_CR29","doi-asserted-by":"publisher","first-page":"e114260","DOI":"10.1371\/journal.pone.0114260","volume":"9","author":"S Rahim","year":"2014","unstructured":"Rahim, S. et al. A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model. PLoS One 9, e114260 (2014).","journal-title":"PLoS One"},{"key":"48397_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s40425-019-0752-4","volume":"7","author":"YQ Wang","year":"2019","unstructured":"Wang, Y. Q. et al. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. J. Immunother. Cancer 7, 298 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"48397_CR31","doi-asserted-by":"crossref","unstructured":"Mikhailova, E. V. et al. Fli1 and Tissue Fibrosis in Various Diseases. Int. J. Mol. Sci. 24, 1881 (2023).","DOI":"10.3390\/ijms24031881"},{"key":"48397_CR32","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1038\/onc.2014.162","volume":"34","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. The ets transcription factor Fli-1 in development, cancer and disease. Oncogene 34, 2022\u20132031 (2015).","journal-title":"Oncogene"},{"key":"48397_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03986-y","volume":"21","author":"E Chen","year":"2023","unstructured":"Chen, E. et al. FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K\/AKT signaling pathway. J. Transl Med. 21, 134 (2023).","journal-title":"J. Transl Med."},{"key":"48397_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","volume":"11","author":"M Liu","year":"2018","unstructured":"Liu, M. et al. Targeting the IDO1 pathway in cancer: from bench to bedside. J. Hematol. Oncol. 11, 100 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"48397_CR35","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","volume":"115","author":"X Liu","year":"2010","unstructured":"Liu, X. et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115, 3520\u20133530 (2010).","journal-title":"Blood"},{"key":"48397_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","volume":"4","author":"M Toulmonde","year":"2018","unstructured":"Toulmonde, M. et al. Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial. JAMA Oncol. 4, 93\u201397 (2018).","journal-title":"JAMA Oncol."},{"key":"48397_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.imlet.2015.11.012","volume":"169","author":"A Ben-Haj-Ayed","year":"2016","unstructured":"Ben-Haj-Ayed, A. et al. Prognostic value of indoleamine 2,3-dioxygenase activity and expression in nasopharyngeal carcinoma. Immunol. Lett. 169, 23\u201332 (2016).","journal-title":"Immunol. Lett."},{"key":"48397_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","volume":"19","author":"L Kraehenbuehl","year":"2022","unstructured":"Kraehenbuehl, L. et al. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19, 37\u201350 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"48397_CR39","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.cell.2020.07.038","volume":"182","author":"A Sadik","year":"2020","unstructured":"Sadik, A. et al. IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell 182, 1252\u20131270.e34 (2020).","journal-title":"Cell"},{"key":"48397_CR40","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3389\/fimmu.2019.01801","volume":"10","author":"J G\u00fcnther","year":"2019","unstructured":"G\u00fcnther, J., D\u00e4britz, J. & Wirthgen, E. Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment. Front. Immunol. 10, 1801 (2019).","journal-title":"Front. Immunol."},{"key":"48397_CR41","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.ccell.2022.11.005","volume":"40","author":"Z Ma","year":"2022","unstructured":"Ma, Z. et al. Interferon-dependent SLC14A1(+) cancer-associated fibroblasts promote cancer stemness via WNT5A in bladder cancer. Cancer Cell 40, 1550\u20131565.e7 (2022).","journal-title":"Cancer Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48397-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48397-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48397-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T06:24:33Z","timestamp":1717050273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-48397-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,30]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["48397"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-48397-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,30]]},"assertion":[{"value":"15 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4590"}}